Øyvind Bruland

• Hompland, Ivar; Pedersen, Kjetil Boye; Wiedswang, Anne Marit; Papakonstantinou, Andri; Røsok, Bård Ingvald & Joensuu, Heikki [Show all 7 contributors for this article] (2024). Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study. Acta Oncologica. ISSN 0284-186X. 63, p. 288–293. doi: 10.2340/1651-226X.2024.39851.
• Machak, Gennady N.; Bruland, Øyvind; Romanova, Tamara N. & Kovalev, Alexey V. (2024). Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal. Journal of Bone Oncology. ISSN 2212-1366. 45. doi: 10.1016/j.jbo.2024.100596.
• Palmerini, Emanuela; Reichardt, Peter; Hall, Kirsten Sundby; Bertulli, Rossella; Bielack, Stefan S. & Comandone, Alessandro [Show all 18 contributors for this article] (2023). Outcome of rare primary malignant bone sarcoma (RPMBS) treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S). Cancer. ISSN 0008-543X. doi: 10.1002/cncr.34964. Full text in Research Archive
• Thorgersen, Ebbe Billmann; Asvall, Jørund; Schjalm, Camilla; Ekholt, Karin; Bruland, Øyvind & Larsen, Stein Gunnar [Show all 7 contributors for this article] (2023). Effect of Intraperitoneal ²²⁴Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy. Technology in Cancer Research & Treatment (TCRT). ISSN 1533-0346. 22. doi: 10.1177/15330338231192902. Full text in Research Archive
• Mensali, Nadia; Köksal, Hakan; Joaquina, Sandy; Vernhoff, Håkan Patrik; Casey, Nicholas Paul & Romecin, Paola [Show all 27 contributors for this article] (2023). ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nature Communications. ISSN 2041-1723. 14. doi: 10.1038/s41467-023-39097-x. Full text in Research Archive
• Fauske, Lena; Jebsen, Nina Louise; Bondevik, Hilde & Bruland, Øyvind (2023). Exploring the Patient Perspective of Bone Sarcoma Survivors Who Have Undergone Particle Radiotherapy Abroad. Anticancer Research. ISSN 0250-7005. 43(5), p. 2031–2039. doi: 10.21873/anticanres.16364. Full text in Research Archive
• van de Wal, Deborah; Fauske, Lena; Bruland, Øyvind; Jones, Robin L.; Kasper, Bernd & Wilson, Roger [Show all 8 contributors for this article] (2023). Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists. Supportive Care in Cancer. ISSN 0941-4355. 31(6). doi: 10.1007/s00520-023-07810-7. Full text in Research Archive
• Larsen, Stein Gunnar; Graf, Wilhelm; Mariathasan, Anthony Burton; Sørensen, Olaf; Spasojevic, Milan & Goscinski, Mariusz Adam [Show all 11 contributors for this article] (2023). First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study). Frontiers in medicine. ISSN 2296-858X. 10. doi: 10.3389/fmed.2023.1070362. Full text in Research Archive Show summary

  Background: Peritoneal metastasis (PM) from colorectal cancer carries a dismal prognosis despite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). With a median time to recurrence of 11–12 months, there is a need for novel therapies. Radspherin® consists of the α-emitting radionuclide radium-224 (224Ra), which has a half-life of 3.6 days and is adsorbed to a suspension of biodegradable calcium carbonate microparticles that are designed to give short-range radiation to the serosal peritoneal surface linings, killing free-floating and/or tumor cell clusters that remain after CRS-HIPEC. Methods: A first-in-human phase 1 study (EudraCT 2018–002803-33) was conducted at two specialized CRS-HIPEC centers. Radspherin® was administered intraperitoneally 2 days after CRS-HIPEC. Dose escalation at increasing activity dose levels of 1-2-4-7-MBq, a split-dose repeated injection, and expansion cohorts were used to evaluate the safety and tolerability of Radspherin®. The aim was to explore the recommended dose and biodistribution using gamma-camera imaging. The results from the planned safety interim analysis after the completion of the dose-limiting toxicity (DLT) period of 30 days are presented. Results: Twenty-three patients were enrolled: 14 in the dose escalation cohort, three in the repeated cohort, and six in the expansion cohort. Of the 23 enrolled patients, seven were men and 16 were women with a median age of 64 years (28–78). Twelve patients had synchronous PM stage IV and 11 patients had metachronous PM [primary stage II; (6) and stage III; (5)], with a disease-free interval of 15 months (3–30). The peritoneal cancer index was median 7 (3–19), operation time was 395 min (194–515), and hospital stay was 12 days (7–37). A total of 68 grade 2 adverse events were reported for 17 patients during the first 30 days; most were considered related to CRS and/or HIPEC. Only six of the TEAEs were evaluated as related to Radspherin®. One TEAE, anastomotic leakage, was reported as grade 3. Accordion ≥3 grade events occurred in a total of four of the 23 patients: reoperation due to anastomotic leaks (two) and drained abscesses (two). No DLT was documented at the 7 MBq dose level that was then defined as the recommended dose. The biodistribution of Radspherin® showed a relatively even peritoneal distribution. Conclusion: All dose levels of Radspherin® were well tolerated, and DLT was not reached. No deaths occurred, and no serious adverse events were considered related to Radspherin®.

• Grønningsæter, Simen Rykkje; Blakkisrud, Johan; Selboe, Silje; Rootwelt-Revheim, Mona Elisabeth; Bruland, Øyvind & Bønsdorff, Tina Bjørnlund [Show all 8 contributors for this article] (2023). Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis. Frontiers in medicine. ISSN 2296-858X. 10, p. 1–10. doi: 10.3389/fmed.2023.1058914. Full text in Research Archive
• Juzenienne, Asta; Stenberg, Vilde Yuli; Bruland, Øyvind; Rootwelt-Revheim, Mona Elisabeth & Larsen, Roy Hartvig (2023). Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach. Frontiers in medicine. ISSN 2296-858X. 9:1051825, p. 1–12. doi: 10.3389/fmed.2022.1051825. Full text in Research Archive
• Schmid, Maximilian P.; Harrabi, Semi; Herfarth, Klaus; Bruland, Øyvind; Welzel, Thomas & Haberer, Thomas [Show all 10 contributors for this article] (2022). Particle Therapy in Adult Patients with Pelvic Ewing Sarcoma—Tumor and Treatment Characteristics and Early Clinical Outcomes. Cancers. ISSN 2072-6694. 14(24). doi: 10.3390/cancers14246045.
• Tornes, Anna Julie Kjøl; Stenberg, Vilde Yuli; Bruland, Øyvind; Rootwelt-Revheim, Mona Elisabeth; Larsen, Roy H & Juzenienne, Asta (2022). Targeted alpha therapy with the ²²⁴Ra/²¹²Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma. Frontiers in medicine. ISSN 2296-858X. 9. doi: 10.3389/fmed.2022.1058863. Full text in Research Archive
• Boye, Kjetil ; Lobmaier, Ingvild Victoria Koren; Kobbeltvedt, Marthe Rosvoll; Thorkildsen, Joachim; Taksdal, Ingeborg & Bjerkehagen, Bodil [Show all 10 contributors for this article] (2022). Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study. Acta Oncologica. ISSN 0284-186X. 61(7), p. 793–800. doi: 10.1080/0284186X.2022.2082259. Full text in Research Archive
• Barnes, David J.; Dutton, Peter; Bruland, Øyvind; Gelderblom, Hans; Faleti, Ade & Bühnemann, Claudia [Show all 26 contributors for this article] (2022). Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial). BMC Cancer. ISSN 1471-2407. 22(1). doi: 10.1186/s12885-022-09697-9. Full text in Research Archive
• Stenberg, Vilde Yuli; Tornes, Anna Julie Kjøl; Nilsen, Hogne Røed; Rootwelt-Revheim, Mona Elisabeth; Bruland, Øyvind & Larsen, Roy Hartvig [Show all 7 contributors for this article] (2022). Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001. Cancers. ISSN 2072-6694. 14(11). doi: 10.3390/cancers14112784. Full text in Research Archive
• Fauske, Lena; Wærstad, Pernille Holter; Hompland, Ivar & Bruland, Øyvind (2022). Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours. Anticancer Research. ISSN 0250-7005. 42(2), p. 955–963. doi: 10.21873/anticanres.15555.
• Stenberg, Vilde Yuli; Larsen, Roy H.; Ma, Li-Wei; Qian, Peng; Juzenas, Petras & Bruland, Øyvind [Show all 7 contributors for this article] (2021). Evaluation of the psma-binding ligand²¹²pb-ng001 in multicellular tumour spheroid and mouse models of prostate cancer. International Journal of Molecular Sciences. ISSN 1661-6596. 22(9). doi: 10.3390/ijms22094815.
• Rootwelt-Revheim, Mona Elisabeth; Hole, Knut Håkon; Mo, Torgeir; Bruland, Øyvind; Reitan, Edmund & Julsrud, Lars [Show all 7 contributors for this article] (2021). Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors. Acta Radiologica. ISSN 0284-1851. 63(8), p. 995–1004. doi: 10.1177/02841851211027389. Full text in Research Archive Show summary

  Background: Several imaging modalities are used in the early work-up of patients with gastrointestinal stromal tumor (GIST) receiving tyrosine kinase inhibitor (TKI) treatment and there is a need to establish whether they provide similar or complimentary information. Purpose: To compare 18F-fluorodeoxyglucose positron emission tomography (FDG PET), computed tomography (CT) and magnetic resonance imaging (MRI) as early predictors of three-month outcomes for patients with GIST receiving TKI treatment. Material and methods: Thirty-five patients with advanced GIST were prospectively included between February 2011 and June 2017. FDG PET, contrast-enhanced CT (CECT), and MRI were performed before and early after onset of TKI treatment (range 8-18 days). Early response was categorized according to mRECIST (CT), the Choi criteria (CECT), and PERCIST (FDG PET/CT). For MRI, volumetry from T2-weighted images and change in apparent diffusion coefficient (ADC) from diffusion-weighted imaging was used. The reference standard for early assessment was the three-month mRECIST evaluation based on CT. At three months, both stable disease (SD) and partial response (PR) were categorized as response. Clinical usefulness was defined as agreement between early and three-month assessment. Results: At the three-month assessment, 91% (32/35) were responders, 37% (13/35) PR, 54% (19/35) SD, and 9% (3/35) had progressive disease (PD). Early assessment correctly predicted three-month response in 93% (27/29) for MRI, 80% (28/35) for PERCIST, 74% (26/35) for Choi, and 23% (8/35) for mRECIST. Six patients had non-FDG-avid tumors. For the FDG-avid tumors, PET/CT correctly predicted three-month response in 97% (28/29). Conclusion: MRI was superior to CECT for early assessment of TKI-treatment response in GIST. If the tumor was FDG-avid, PET and MRI were equally good. Changes in functional parameters were superior to changes in longest tumor diameter (mRECIST).

• van Eck, Ilse; Den Hollander, Dide; Lidington, Emma; Hentschel, Leopold; Eichler, Martin & Salah, Samer [Show all 21 contributors for this article] (2021). Health-related quality of life issues experienced by thoracic and breast sarcoma patients: A rare and understudied group. Journal of Clinical Medicine. ISSN 2077-0383. 10(22). doi: 10.3390/jcm10225334.
• Kerboeuf, Mikael Mathias Kolmannskog; Koppang, Erling Olaf; Haaland, Anita Haug; Lingaas, Frode; Bruland, Øyvind & Teige, Jon [Show all 7 contributors for this article] (2021). Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma. Acta Veterinaria Scandinavica (AVS). ISSN 0044-605X. 63(1), p. 1–10. doi: 10.1186/s13028-021-00608-9. Full text in Research Archive
• Spasojevic, Milan; Mariathasan, Anthony Burton; Frich, Lars Inge; Bruland, Øyvind; Larsen, Stein G. & Stoldt, Stephan (2021). Kreftbehandling med isolert ekstremitetsperfusjon. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 141(12), p. 1–6. doi: 10.4045/tidsskr.21.0194. Full text in Research Archive
• Napoli, Elisa; Bønsdorff, Tina Bjørnlund; Jorstad, Ida Sofie; Bruland, Øyvind; Larsen, Roy H. & Westrøm, Sara (2021). Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use. PLOS ONE. ISSN 1932-6203. 16(3), p. 1–18. doi: 10.1371/journal.pone.0248133. Full text in Research Archive
• Fauske, Lena; Bruland, Øyvind; Dahl, Alv A; Myklebostad, Åse & Reme, Silje Endresen (2021). Does the lightning process training programme reduce chronic fatigue in adolescent and young adult cancer survivors? A mixed-methods pilot study. Cancers. ISSN 2072-6694. 13(16), p. 1–13. doi: 10.3390/cancers13164076. Full text in Research Archive Show summary

  Chronic fatigue is a common late adverse effect following oncological therapies. No effective treatments exist, although cognitive behaviour therapy has been reported to offer some benefits. The Lightning Process® is a three-day educational training programme with a six-month follow-up comprising elements derived from cognitive behaviour therapy, neurolinguistic programming, and stress theory, which are presented in a condensed form. This pilot intervention study represents the first systematic account of the experience and perceived efficacy of the LP training programme in 13 adolescent and young adult cancer survivors treated for sarcoma or Hodgkin lymphoma. Statistically significant improvements were documented for all the patient-reported outcome measure (PROM) questionnaires comparing the pre- and post-intervention periods. The qualitative findings of the interviews corresponded well with the PROMs findings, as participants emphasised that they now experienced both less fatigue and explicit improvement in their energy level.

• Li, Ruth Gong; Napoli, Elisa; Jorstad, Ida Sofie; Bønsdorff, Tina Bjørnlund; Juzeniene, Asta & Bruland, Øyvind Sverre [Show all 8 contributors for this article] (2021). Calcium carbonate microparticles as carriers of 224Ra: Impact of specific activity in mice with intraperitoneal ovarian cancer. Current Radiopharmaceuticals. ISSN 1874-4710. 14(2), p. 145–153. doi: 10.2174/1874471013666201201102056. Full text in Research Archive
• Juzeniene, Asta; Stenberg, Vilde Yuli; Bruland, Øyvind & Larsen, Roy Hartvig (2021). Preclinical and clinical status of psma-targeted alpha therapy for metastatic castration-resistant prostate cancer. Cancers. ISSN 2072-6694. 13:779(4), p. 1–25. doi: 10.3390/cancers13040779. Full text in Research Archive
• Hall, Kirsten Sundby; Bruland, Øyvind; Bjerkehagen, Bodil; Lidbrink, Elisabet; Jebsen, Nina Louise & Hagberg, Hans [Show all 11 contributors for this article] (2020). Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study. Clinical Sarcoma Research. ISSN 2045-3329. doi: 10.1186/s13569-020-00145-5. Full text in Research Archive Show summary

  Background We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, group B, comprised of patients in a defined cohort with locally advanced STS considered at high risk for intralesional surgery. These patients received preoperative accelerated radiotherapy, together with neoadjuvant and adjuvant chemotherapy. Herein we report the results of this group B. Methods Twenty patients with high-grade, locally advanced and deep STS located in lower extremities (n = 12), upper extremities (5) or trunk wall (3) were included. The median age was 59 years and 14 patients were males. The treatment regimen consisted of 6 cycles of doxorubicin (60 mg/m2) and ifosfamide (6 g/m2), with three cycles given neoadjuvantly, and preoperative radiotherapy (1, 8 Gyx2/daily to 36 Gy) between cycles 2 and 3. After a repeated MRI surgery was then conducted, and the remaining 3 chemotherapy cycles were given postoperatively at 3 weeks intervals. Survival data, local control, toxicity of chemotherapy and postoperative complications are presented. Results Median follow-up time for metastasis-free survival (MFS) was 2.8 years (range 0.3–10.4). The 5-year MFS was 49.5% (95% confidence interval [CI] 31.7–77.4). The median follow-up time was 5.4 years (range 0.3–10.4) for overall survival (OS). The 5-year OS was 64.0% (95% CI 45.8–89.4). The median tumour size was 13 cm, with undifferentiated pleomorphic sarcoma (n = 10) and synovial sarcoma (n = 6) diagnosed most frequently. All patients completed surgery. Resection margins were R0 in 19 patients and R1 in 1 patient. No patients had evidence of disease progression preoperatively. Three patients experienced a local recurrence, in 2 after lung metastases had already been diagnosed. Eleven patients (55%) had postoperative wound problems (temporary in 8 and persistent in 3). Conclusions Preoperative chemotherapy and radiotherapy were associated with temporary wound-healing problems. Survival outcomes, local control and toxicities were deemed satisfactory when considering the locally advanced sarcoma disease status at primary diagnosis.

• Stenberg, Vilde Yuli; Juzeniene, Asta; Chen, Qingqi; Yang, Xiaoming; Bruland, Øyvind & Larsen, Roy Hartvig (2020). Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer. Journal of labelled compounds & radiopharmaceuticals. ISSN 0362-4803. 63(3), p. 129–143. doi: 10.1002/jlcr.3825. Full text in Research Archive
• Lansu, Jules; Bovée, Judith V.M.G.; Braam, Pètra; van Boven, Hester; Flucke, Uta & Bonenkamp, Johannes J. [Show all 24 contributors for this article] (2020). Dose reduction of preoperative radiotherapy in myxoid liposarcoma: A nonrandomized controlled trial. JAMA Oncology. ISSN 2374-2437. p. 1–8. doi: 10.1001/jamaoncol.2020.5865.
• Radaelli, S.; Fossati, Piero; Stacchiotti, S.; Akiyama, T.; Asencio, J.M. & Bandiera, S. [Show all 68 contributors for this article] (2020). The sacral chordoma margin. European Journal of Surgical Oncology. ISSN 0748-7983. 46(8), p. 1415–1422. doi: 10.1016/j.ejso.2020.04.028. Full text in Research Archive
• Coleman, Robert; Hadji, Peyman; Body, Jean-Jacques; Santini, Daniele; Chow, Edward L.W. & Terpos, Evangelos [Show all 13 contributors for this article] (2020). Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. ISSN 0923-7534. p. 1–14. doi: 10.1016/j.annonc.2020.07.019.
• Hompland, Ivar; Fauske, Lena; Lorem, Geir F & Bruland, Øyvind (2020). Use of a simple form to facilitate communication on long‑term consequences of treatment in sarcoma survivors. Clinical Sarcoma Research. ISSN 2045-3329. doi: 10.1186/s13569-019-0124-3. Full text in Research Archive
• Napoli, Elisa; Stenberg, Vilde Yuli; Juzeniene, Asta; Hjellum, Gro E.; Bruland, Øyvind & Larsen, Roy H. (2020). Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples. Applied Radiation and Isotopes. ISSN 0969-8043. 166:109362, p. 1–9. doi: 10.1016/j.apradiso.2020.109362. Full text in Research Archive
• Stenberg, Vilde Yuli; Juzeniene, Asta; Bruland, Øyvind & Larsen, Roy H. (2020). In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells. Current Radiopharmaceuticals. ISSN 1874-4710. 13(2), p. 130–141. doi: 10.2174/1874471013666200511000532. Full text in Research Archive
• König, Marton; Osnes, Terje; Bruland, Øyvind; Hall, Kirsten Sundby; Bratland, Åse & Meling, Torstein Ragnar (2020). The role of adjuvant treatment in craniofacial malignancy: A critical review . Frontiers in Oncology. ISSN 2234-943X. 10. doi: 10.3389/fonc.2020.01402. Full text in Research Archive
• Berner, Kjetil & Bruland, Øyvind (2019). Prognostic impact of proximal versus distal localization in extremity long bone osteosarcomas. Anticancer Research. ISSN 0250-7005. 39(5), p. 2459–2466. doi: 10.21873/anticanres.13365.
• Fauske, Lena; Hompland, Ivar; Lorem, Geir F; Bondevik, Hilde & Bruland, Øyvind (2019). Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. Clinical Sarcoma Research. ISSN 2045-3329. 9(6). doi: 10.1186/s13569-019-0116-3. Full text in Research Archive
• Jha, Anjani Kumar; Neupane, Pradeep; Pradhan, Manohar; Sharma, Krishna Sagar; Shrestha, Sadina & Sigdel, Padma Raj [Show all 8 contributors for this article] (2019). Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy . Journal of Global Oncology (JGO). ISSN 2378-9506. 2019(5), p. 1–10. doi: 10.1200/JGO.19.00015. Full text in Research Archive
• Köksal, Hakan; Müller, Elisabeth; Inderberg, Else Marit ; Bruland, Øyvind & Wälchli, Sébastien (2019). Treating osteosarcoma with CAR T cells. Scandinavian Journal of Immunology. ISSN 0300-9475. 89:e12741(3), p. 1–8. doi: 10.1111/sji.12741. Full text in Research Archive
• Berner, Kjetil; Johannessen, Tom Børge; Hall, Kirsten Sundby & Bruland, Øyvind (2019). Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study. Journal of Bone Oncology. ISSN 2212-1366. 14. doi: 10.1016/j.jbo.2018.11.002. Full text in Research Archive
• Thorkildsen, Joachim; Taksdal, Ingeborg ; Bjerkehagen, Bodil; Haugland, Hans Kristian; Johannessen, Tom Børge & Viset, Trond [Show all 9 contributors for this article] (2019). Chondrosarcoma in Norway 1990-2013; an epidemiological and prognostic observational study of a complete national cohort. Acta Oncologica. ISSN 0284-186X. p. 273–282. doi: 10.1080/0284186X.2018.1554260. Full text in Research Archive
• Hesla, Asle Charles; Bruland, Øyvind; Jebsen, Nina Louise; Styring, Emelie; Eriksson, Sigvard & Tsagozis, Panagiotis (2018). Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years. Journal of Bone Oncology. ISSN 2212-1366. 14, p. 1–9. doi: 10.1016/j.jbo.2018.100216.
• Hompland, Ivar; Hølmebakk, Søren Torben; Pedersen, Kjetil Boye; Stoldt, Stephan; Bjerkehagen, Bodil & Berner, Jeanne-Marie [Show all 11 contributors for this article] (2018). Multimodal kreftbehandling av gastrointestinal stromal tumor. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 138(15). doi: 10.4045/tidsskr.18.0200.
• Heinrich, Daniel; Bruland, Øyvind; Guise, Theresa A.; Suzuki, Hiroyoshi & Sartor, Oliver (2018). Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker. Future Oncology. ISSN 1479-6694. 14(24), p. 2543–2556. doi: 10.2217/fon-2018-0087.
• Westrøm, Sara; Malenge, Marion Masitsa; Jorstad, Ida Sofie; Napoli, Elisa; Bruland, Øyvind & Bønsdorff, Tina Bjørnlund [Show all 7 contributors for this article] (2018). Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice. Journal of labelled compounds & radiopharmaceuticals. ISSN 0362-4803. 61(6), p. 472–486. doi: 10.1002/jlcr.3610. Full text in Research Archive
• Hølmebakk, Søren Torben; Hompland, Ivar; Bjerkehagen, Bodil; Stoldt, Stephan; Bruland, Øyvind & Hall, Kirsten Sundby [Show all 7 contributors for this article] (2018). Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Annals of Surgical Oncology. ISSN 1068-9265. 25(5), p. 1133–1139. doi: 10.1245/s10434-018-6353-5.
• Westrøm, Sara; Bønsdorff, Tina Bjørnlund; Bruland, Øyvind & Larsen, Roy H. (2018). Therapeutic effect of α-emitting 224Ra-labeled calcium carbonate microparticles in mice with intraperitoneal ovarian cancer. Translational Oncology. ISSN 1944-7124. 11(2), p. 259–267. doi: 10.1016/j.tranon.2017.12.011. Full text in Research Archive
• Pedersen, Kjetil Boye; Berner, Jeanne-Marie; Hompland, Ivar; Bruland, Øyvind; Stoldt, Stephan & Hall, Kirsten Sundby [Show all 8 contributors for this article] (2018). Genotype and risk of tumour rupture in gastrointestinal stromal tumour. British Journal of Surgery. ISSN 0007-1323. 105(2), p. e169–e175. doi: 10.1002/bjs.10743.
• Hall, Kirsten Sundby; Bruland, Øyvind; Bjerkehagen, Bodil; Zaikova, Olga; Engellau, Jacob & Hagberg, Oskar [Show all 15 contributors for this article] (2018). Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX). European Journal of Cancer. ISSN 0959-8049. 99, p. 78–85. doi: 10.1016/j.ejca.2018.05.011.
• Parker, Christopher C.; Coleman, Robert Edward; Sartor, Oliver; Vogelzang, Nicholas J.; Bottomley, David & Heinrich, Daniel [Show all 29 contributors for this article] (2018). Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European Urology. ISSN 0302-2838. 73(3), p. 353–360. doi: 10.1016/j.eururo.2017.06.021.
• Hompland, Ivar; Bruland, Øyvind; Hølmebakk, Søren Torben; Poulsen, Jan Peter; Stoldt, Stephan & Hall, Kirsten Sundby [Show all 7 contributors for this article] (2017). Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncologica. ISSN 0284-186X. 56(10), p. 1317–1323. doi: 10.1080/0284186X.2017.1330555.
• Sartor, Oliver; Coleman, Robert Edward; Nilsson, Sten; Heinrich, Daniel; Helle, Svein Inge & O'Sullivan, Joe M. [Show all 14 contributors for this article] (2017). An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Annals of Oncology. ISSN 0923-7534. 28(5), p. 1090–1097. doi: 10.1093/annonc/mdx044.
• Varghese, Mercy; Bruland, Øyvind; Wiedswang, Anne Marit; Lobmaier, Ingvild Victoria Koren; Røsok, Bård Ingvald & Benjamin, Robert [Show all 7 contributors for this article] (2016). Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature. Clinical Sarcoma Research. ISSN 2045-3329. 6(2). doi: 10.1186/s13569-016-0042-6.
• Hompland, Ivar; Bruland, Øyvind; Ubhayasekhera, Kumari; Bergquist, Jonas & Boye, Kjetil (2016). Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. Clinical Sarcoma Research. ISSN 2045-3329. 6(21). doi: 10.1186/s13569-016-0062-2.
• Parker, Christopher; Finkelstein, Steven E.; Michalski, Jeff M.; O'Sullivan, Joe M.; Bruland, Øyvind & Vogelzang, Nicholas J. [Show all 12 contributors for this article] (2016). Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology. ISSN 0302-2838. 70(5), p. 875–883. doi: 10.1016/j.eururo.2016.06.002.
• König, Marton Skog Steinberger; Osnes, Terje; Lobmaier, Ingvild Victoria Koren; Bjerkehagen, Bodil; Bruland, Øyvind & Hall, Kirsten Sundby [Show all 7 contributors for this article] (2016). Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years. Neurosurgical review. ISSN 0344-5607. p. 1–12. doi: 10.1007/s10143-016-0802-z. Show summary

  High-grade craniofacial osteosarcoma (CFOS) is an aggressive malignancy with a poor prognosis. Our goals were to evaluate treatment outcomes in those treated at a single referral institution over 35 years and to compare our results to the available literature. A retrospective analysis of all 42 patients treated between 1980 and 2015 at Oslo University Hospital, Norway, identified in a prospectively collected database, was conducted. Mean follow-up was 79.6 months. Overall survival at 2 and 5 years was 70.5 and 44.7%, respectively. The corresponding disease-specific survival rates were 73.0 and 49.8%. Treatment was surgery only in eight cases. Additional therapy was administered in 34 patients: chemotherapy in nine, radiotherapy in seven, and a combination of these in 18 cases. Stratified analysis by resection margins demonstrated significantly better survival at 2 and 5 years after radical surgical treatment. Neoadjuvant chemotherapy and subsequent adequate surgery resulted in better survival than surgery alone. Half of the patients either had a primary or familial cancer predisposition. This is the largest single-center study conducted on high-grade CFOS to date. Our experience indicates that neoadjuvant chemotherapy with complete surgical resection significantly improved survival, compared to surgery alone.

• Westrøm, Sara; Bønsdorff, Tina B; Abbas, Nasir; Bruland, Øyvind; Jonasdottir, Thora J & Mælandsmo, Gunhild [Show all 7 contributors for this article] (2016). Evaluation of CD146 as target for radioimmunotherapy against Osteosarcoma. PLOS ONE. ISSN 1932-6203. 11(10). doi: 10.1371/journal.pone.0165382.
• Barøy, Tale; Chilamakuri, Chandra Sekhar Reddy; Lorenz, Susanne; Sun, Jinchang; Bruland, Øyvind & Myklebost, Ola [Show all 7 contributors for this article] (2016). Genome analysis of osteosarcoma progression samples identifies FGFR1 overexpression as a potential treatment target and CHM as a candidate tumor suppressor gene. PLOS ONE. ISSN 1932-6203. doi: 10.1371/journal.pone.0163859.
• Hølmebakk, Søren Torben; Bjerkehagen, Bodil; Pedersen, Kjetil Boye; Bruland, Øyvind; Stoldt, Stephan & Hall, Kirsten Sundby (2016). Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. British Journal of Surgery. ISSN 0007-1323. 103(6), p. 684–691. doi: 10.1002/bjs.10104.
• Berner, Kjetil; Bjerkehagen, Bodil; Bruland, Øyvind & Berner, Aasmund (2015). Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature. Anticancer Research. ISSN 0250-7005. 35(4), p. 2129–2140.
• Hompland, Ivar & Bruland, Øyvind (2015). Can imatinib be safely withdrawn in patients with surgically resected metastatic GIST? Anticancer Research. ISSN 0250-7005. 35(11), p. 5759–5765.
• Berner, Kjetil; Johannessen, Tom Børge & Bruland, Øyvind (2015). Clinical epidemiology of low-grade and dedifferentiated osteosarcoma in Norway during 1975 and 2009. Sarcoma. ISSN 1357-714X. 2015:917679. doi: 10.1155/2015/917679.
• Fauske, Lena; Bondevik, Hilde; Bruland, Øyvind & Ozakinci, Gozde (2015). Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study. Anticancer Research. ISSN 0250-7005. 35(11), p. 6081–6090.
• Juzeniene, Asta; Porojnicu, Alina Carmen; Baturaite, Zivile; Lagunova, Zoya; Aksnes, Lage & Bruland, Øyvind [Show all 7 contributors for this article] (2015). Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas. Anticancer Research. ISSN 0250-7005. 35(2), p. 1171–1180.
• Berner, Kjetil; Hall, Kirsten Sundby; Monge, Odd R; Weedon-Fekjær, Harald; ZAIKOVA, OLGA & Bruland, Øyvind (2015). Prognostic factors and treatment results of high-grade osteosarcoma in Norway: A scope beyond the "classical" patient. Sarcoma. ISSN 1357-714X. 2015. doi: 10.1155/2015/516843.
• Juzeniene, Asta; Baturaite, Zivile; Lagunova, Zoya; Grigalavicius, Mantas; Porojnicu, Alina Carmen & Bruland, Øyvind [Show all 7 contributors for this article] (2015). Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females. Scandinavian Journal of Public Health. ISSN 1403-4948. 43(3), p. 324–330. doi: 10.1177/1403494815572206.
• Humm, John L.; Sartor, Oliver; Parker, Chris; Bruland, Øyvind & Macklis, Roger (2015). Radium-223 in the treatment of osteoblastic metastases: A critical clinical review. International Journal of Radiation Oncology, Biology, Physics. ISSN 0360-3016. 91(5), p. 898–906. doi: 10.1016/j.ijrobp.2014.12.061.
• Anfinsen, Kristin Paaske; Grotmol, Tom; Bruland, Øyvind & Jonasdottir, Thora Johanna (2015). Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence. Preventive Veterinary Medicine. ISSN 0167-5877. 119(1-2), p. 48–53. doi: 10.1016/j.prevetmed.2015.02.003.
• Fauske, Lena; Bruland, Øyvind; Grov, Ellen Karine & Bondevik, Hilde (2015). Cured of Primary Bone Cancer, But at What Cost: A Qualitative Study of Functional Impairment and Lost Opportunities. Sarcoma. ISSN 1357-714X. 2015. doi: 10.1155/2015/484196. Full text in Research Archive
• Berner, Kjetil; Johannesen, Tom Børge; Berner, Aasmund; Haugland, Hans Kristian; Bjerkehagen, Bodil & Bøhler, Per J. [Show all 7 contributors for this article] (2015). Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncologica. ISSN 0284-186X. 54(1), p. 25–33. doi: 10.3109/0284186X.2014.923934.
• Ohnstad, Hege Oma; Bruland, Øyvind; Taksdal, Ingeborg ; Bjerkehagen, Bodil; Nenadovic, Maja & Sæter, Gunnar [Show all 8 contributors for this article] (2014). Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - A predictor of outcome? Acta Oncologica. ISSN 0284-186X. 53(9), p. 1180–1187. doi: 10.3109/0284186X.2014.899433.
• Repetto-Llamazares, Ada H.V.; Abbas, Nasir; Bruland, Øyvind; Dahle, Jostein & Larsen, Roy H. (2014). Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of B-cell tumors. Anticancer Research. ISSN 0250-7005. 34(7), p. 3263–3269.
• Switlyk, Marta Daniela; Bruland, Øyvind; Skjeldal, Sigmund; Hald, John K; Seierstad, Therese & ZAIKOVA, OLGA (2014). Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI. Journal of Bone Oncology. ISSN 2212-1366. 3, p. 5–9. doi: 10.1016/j.jbo.2014.02.003.
• Sartor, Oliver; Coleman, Robert; Nilsson, Sten; Heinrich, Daniel; Helle, Svein Inge & O'Sullivan, Joe M. [Show all 21 contributors for this article] (2014). Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. The Lancet Oncology. ISSN 1470-2045. 15(7), p. 738–746. doi: 10.1016/S1470-2045(14)70183-4.
• Repetto-Llamazares, Ada H.V.; Larsen, Roy H.; Giusti, Anna Maria; Riccardi, Elena; Bruland, Øyvind & Selbo, Pål Kristian [Show all 7 contributors for this article] (2014). 177 Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: A study of toxicity in nude mice. PLOS ONE. ISSN 1932-6203. 9(7). doi: 10.1371/journal.pone.0103070. Full text in Research Archive
• Heyerdahl, Helen; Abbas, Nasir; Sponheim, Kristine; Mollatt, Camilla Sivertsen; Bruland, Øyvind & Dahle, Jostein (2013). Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. Current Radiopharmaceuticals. ISSN 1874-4710. 6(2), p. 106–116. doi: 10.2174/18744710113069990018.
• Lia, K.; Bruland, Øyvind; Randem, H.L.; Aksnes, Liv Hege; Poulsen, Jan Peter & Taksdal, Ingeborg [Show all 7 contributors for this article] (2013). Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma. Journal of Bone Oncology. ISSN 2212-1366. 2(4), p. 174–179. doi: 10.1016/j.jbo.2013.09.002.
• Mikalsen, Lars Tore G; Dhakal, Hari Prasad; Bruland, Øyvind; Naume, Bjørn; Borgen, Elin & Nesland, Jahn M [Show all 7 contributors for this article] (2013). The clinical impact of mean vessel size and solidity in breast carcinoma patients. PLOS ONE. ISSN 1932-6203. 8(10). doi: 10.1371/journal.pone.0075954.
• Rusten, Espen; Rødal, Jan; Bruland, Øyvind & Malinen, Eirik (2013). Biologic targets identified from dynamic (18)FDG-PET and implications for image-guided therapy. Acta Oncologica. ISSN 0284-186X. 52(7), p. 1378–1383. doi: 10.3109/0284186X.2013.813071.
• Lagunova, Zoya; Porojnicu, Alina Carmen; Aksnes, Lage; Holick, Michael F.; Iani, Vladimir & Bruland, Øyvind [Show all 7 contributors for this article] (2013). Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial. British Journal of Dermatology. ISSN 0007-0963. 169(2), p. 434–440. doi: 10.1111/bjd.12349.
• Parker, Christopher; Nilsson, Sten; Heinrich, Daniel; Helle, Svein Inge; O'Sullivan, Joe M. & Fosså, Sophie Dorothea [Show all 30 contributors for this article] (2013). Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. New England Journal of Medicine. ISSN 0028-4793. 369(3), p. 213–223. doi: 10.1056/NEJMoa1213755.
• Jebsen, Nina; Engellau, Jacob; Engström, Katarina; Bauer, Henrik C.; Monge, Odd R & Muren, Ludvig Paul [Show all 9 contributors for this article] (2013). Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. International Journal of Radiation Oncology, Biology, Physics. ISSN 0360-3016. 86(5), p. 949–955. doi: 10.1016/j.ijrobp.2013.04.015. Full text in Research Archive
• Bjerkehagen, Bodil; Småstuen, Milada C; Hall, Kirsten Sundby; Skjeldal, Sigmund; Bruland, Øyvind & Smeland, Sigbjørn [Show all 8 contributors for this article] (2013). Incidence and mortality of second sarcomas – A population-based study. European Journal of Cancer. ISSN 0959-8049. 49(15), p. 3292–3302. doi: 10.1016/j.ejca.2013.05.017.
• Sartor, Oliver; Hoskin, Peter & Bruland, Øyvind (2013). Targeted radio-nuclide therapy of skeletal metastases. Cancer Treatment Reviews. ISSN 0305-7372. 39(1), p. 18–26. doi: 10.1016/j.ctrv.2012.03.006.
• Dahle, Jostein; Repetto-Llamazares, Ada H.V.; Mollatt, Camilla Sivertsen; Melhus, Katrine Brustad; Bruland, Øyvind & Kolstad, Arne [Show all 7 contributors for this article] (2013). Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma. Anticancer Research. ISSN 0250-7005. 33(1), p. 85–96.
• Nilsson, Sten; Franzen, Lars; Parker, Christopher; Tyrrell, Christopher; Blom, René & Tennvall, Jan [Show all 15 contributors for this article] (2013). Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. Clinical Genitourinary Cancer. ISSN 1558-7673. 11(1), p. 20–26. doi: 10.1016/j.clgc.2012.07.002.
• Revheim, Mona Elisabeth; Kristian, Alexandr; Malinen, Eirik; Bruland, Øyvind; Berner, Jeanne-Marie & Holm, Ruth [Show all 8 contributors for this article] (2013). Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncologica. ISSN 0284-186X. 52(4), p. 776–782. doi: 10.3109/0284186X.2013.770920.
• Rusten, Espen; Rødal, Jan; Revheim, Mona Elisabeth; Skretting, Arne; Bruland, Øyvind & Malinen, Eirik (2013). Quantitative dynamic 18 FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncologica. ISSN 0284-186X. 52(6), p. 1160–1167. doi: 10.3109/0284186X.2012.728713.
• Micu, Emanuela; Baturaite, Zivile; Juzeniene, Asta; Bruland, Øyvind & Moan, Johan Emilian (2012). Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients. Melanoma research. ISSN 0960-8931. 22(6), p. 460–465. doi: 10.1097/CMR.0b013e3283599cc3.
• Abbas, Nasir; Bruland, Øyvind; Brevik, Ellen Mengshoel & Dahle, Jostein (2012). Preclinical evaluation of Th-227-labeled and Lu-177-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. Nuclear medicine communications. ISSN 0143-3636. 33(8), p. 838–847. doi: 10.1097/MNM.0b013e328354df7c.
• Nilsson, S.; Strang, P.; Aksnes, A. K.; Franzèn, Lars; Olivier, P & Pecking, A. [Show all 10 contributors for this article] (2012). A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer. ISSN 0959-8049. 48(5), p. 678–686. doi: 10.1016/j.ejca.2011.12.023.

View all works in Cristin

• Juzeniene, Asta; Baum, Richard Paul; Bruland, Øyvind & Larsen, Roy (2023). Targeted Alpha Particle Therapy in Oncology. Frontiers in Medicine. ISBN 978-2-83251-983-7. 186 p.

View all works in Cristin

• Ondrckova, Camilla; Bruland, Øyvind; Tasken, Kjetil & REvheim, Mona E (2023). 15 millioner til forskningsprosjekt: - Bare starten på et kjempestort kapittel innen kreftbehandling. [Internet]. Dagen Medisin.
• Bruland, Øyvind; Larsen, Roy Hartvig; Baum, Richard Paul & Juzenienne, Asta (2023). Editorial: Targeted alpha particle therapy in oncology. Frontiers in medicine. ISSN 2296-858X. 10. doi: 10.3389/fmed.2023.1165747.
• Berner, Kjetil; Zaikova, Olga; Johannessen, Tom Børge; Hall, Kirsten Sundby & Bruland, Øyvind (2018). Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway. Journal of Surgical Oncology. ISSN 0022-4790. 118(1), p. 246–247. doi: 10.1002/jso.25137.
• Herlofson, Bente Brokstad; Kjølle, Gry Karina; Westgaard, Kristine Løken; Løndalen, Ayca & Bruland, Øyvind (2018). Osteonecrosis of the jaw in a patient with bone metastatic prostate cancer after long-term bisphosphonate treatment with severe deterioration following radium-223. Clinical Genitourinary Cancer. ISSN 1558-7673. p. 1–4. doi: 10.1016/j.clgc.2018.05.003.
• König, Marton Skog Steinberger; Osnes, Terje; Lobmaier, Ingvild Victoria Koren; Bjerkehagen, Bodil; Bruland, Øyvind & Sundby Hall, Kirsten [Show all 7 contributors for this article] (2016). Treatment of Craniofacial Osteosarcoma: a Multidisciplinary Approach.
• König, Marton Skog Steinberger; Osnes, Terje; Lobmaier, Ingvild Victoria Koren; Bjerkehagen, Bodil; Bruland, Øyvind & Sundby Hall, Kirsten [Show all 7 contributors for this article] (2016). Craniofacial Osteosarcoma: A Single-Institution Experience.
• Anfinsen, Kristin Paaske; Grotmol, Tom; Bruland, Øyvind; Trangerud, Cathrine & Jonasdottir, Thora Johanna (2015). Corrigendum to "Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence" [Prev. Vet. Med. 119 (2015) 48-53]. Preventive Veterinary Medicine. ISSN 0167-5877. 120(2). doi: 10.1016/j.prevetmed.2015.03.015.
• Westrøm, Sara; Abbas, Nasir; Larsen, Roy Hartvig; Bruland, Øyvind; Jonasdottir, Thora Johanna & Bønsdorff, Tina Bjørnlund (2014). Initial evaluation of a CD146/MUC18 targeting radioimmunoconjugate.
• Revheim, Mona Elisabeth; Hole, Knut Håkon; Bruland, Øyvind; Reitan, Edmund; Bjerkehagen, Bodil & Julsrud, Lars [Show all 7 contributors for this article] (2014). Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta Oncologica. ISSN 0284-186X. 53(1), p. 143–148. doi: 10.3109/0284186X.2013.798428.

View all works in Cristin